EXHIBIT
      31.2







CERTIFICATION
        PURSUANT TO RULE 13a-14(a)/15d-14(a)
 OF
        THE
        SECURITIES EXCHANGE ACT OF 1934
 
 In
        connection with the Quarterly Report of DOR BioPharma, Inc. (the “Company”) on
        Form 10-QSB for the fiscal quarter ended September 30, 2007, as filed with
        the
        Securities and Exchange Commission on the date hereof, I, Evan Myrianthopoulos,
        Chief Financial Officer of the Company, certify, pursuant to Rule 13a-14(a)
        of the Securities Exchange Act of 1934, that:
 
 1.
        I have
        reviewed the Quarterly Report on Form 10-QSB of the Company for the quarter
        year
        ended September 30, 2007;
 
 2.
        Based
        on my knowledge, this report does not contain any untrue statement of a material
        fact or omit to state a material fact necessary to make the statements made,
        in
        light of the circumstances under which such statements were made, not misleading
        with respect to the period covered by this report;
 
 3.
        Based
        on my knowledge, the financial statements, and other financial information
        included in this report, fairly present in all material respects the financial
        condition, results of operations and cash flows of the small business issuer
        as
        of, and for, the periods presented in this report;
 
 4.
        The
        small business issuer’s other certifying officer and I are responsible for
        establishing and maintaining disclosure controls and procedures (as defined
        in
        Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer
        and have:
 
 (a)
        Designed such disclosure controls and procedures, or caused such disclosure
        controls and procedures to be designed under our supervision, to ensure that
        material information relating to the small business issuer, including its
        consolidated subsidiaries, is made known to us by others within those entities,
        particularly during the period in which this report is being
        prepared;
 
 (b)
        Evaluated the effectiveness of the small business issuer’s disclosure controls
        and procedures and presented in this report our conclusions about the
        effectiveness of the disclosure controls and procedures, as of the end of
        the
        period covered by this report based on such evaluation; and
 
 (c)
        Disclosed in this report any change in the small business issuer’s internal
        control over financial reporting that occurred during the small business
        issuer’s most recent fiscal quarter (the small business issuer’s fourth fiscal
        quarter in the case of an annual report) that has materially affected, or
        is
        reasonably likely to materially affect, the small business issuer’s internal
        control over financial reporting; and
 
 5.
        The
        small business issuer’s other certifying officer and I have disclosed, based on
        our most recent evaluation of internal control over financial reporting,
        to the
        small business issuer’s auditors and the audit committee of the small business
        issuer’s board of directors (or persons performing the equivalent
        functions):
 
 (a)           All
        significant deficiencies and material weaknesses in the design or operation
        of
        internal control over financial reporting which are reasonably likely to
        adversely affect the r small business issuer’s ability to record, process,
        summarize and report financial information; and
 
 (b)           Any
        fraud, whether or not material, that involves management or other employees
        who
        have a significant role in the small business issuer’s internal control over
        financial reporting.





**DOR
      BIOPHARMA,
      INC.**





November
                14, 2007
            by:
            **/s/
                Evan Myrianthopoulos**Evan
                MyrianthopoulosChief
                Financial Officer(Principal
                Financial Officer and Principal Accounting Officer)